FDA Panel Meeting to Mull Adding Peptides to Compounding List
FDA has announced a 7/23-24 Pharmacy Compounding Advisory Committee meeting to discuss adding certain peptides to the agency’s 503A Bulks List. The meeting is presumably part of HHS’ move to reverse a 2023 FDA decision that deemed a group of peptide drugs too risky for use by compounding pharmacies.
HHS secretary Robert F. Kennedy Jr. has criticized FDA’s earlier action as “illegal,” arguing the agency overstepped its authority by evaluating the effectiveness of the substances rather than focusing solely on safety, according to ProPublica. Speaking on The Joe Rogan Experience, Kennedy recently said regulators lacked sufficient evidence of harm to justify restricting the peptides.
However, several former FDA officials dispute that claim, saying the agency’s decision was grounded in documented safety risks and consistent with longstanding regulatory standards requiring evaluation of both safety and efficacy. Among them, former acting FDA Commissioner Janet Woodcock warned that reversing the policy could undermine decades of drug oversight, ProPublica reports. “It would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S.,” Woodcock said.
Peptides — short chains of amino acids designed to influence biological processes — have surged in popularity in recent years, particularly among fitness and longevity communities. Despite the growing demand, experts say there has been little new scientific evidence supporting the safety or effectiveness of many of the substances restricted by the agency in 2023.
The agency placed 19 peptides into a category of substances considered too risky for compounding, citing concerns such as immune reactions, contamination risks during manufacturing, and limited clinical data. Some studies involving specific peptides have reported adverse events, including serious complications and deaths, though causation was not always clear. At the same time, demand has fueled a largely unregulated gray market. Wellness clinics, telehealth providers and online vendors often sell so-called “research-grade” peptides labeled as not intended for human use, raising additional safety concerns.
Industry groups, including the Alliance for Pharmacy Compounding, argue that allowing regulated compounders to handle peptides would be safer than leaving consumers to obtain them through unregulated channels. The group acknowledges limited clinical evidence but points to patient testimonials and widespread use as justification for broader access.
Critics counter that such arguments sidestep the core issue of safety and effectiveness. “They’re totally unapproved drugs,” one former FDA official said. “Would you let a pharmaceutical company do this? No.”